The Patent Finder

Terms ending in 2031

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,710,016Actriib Proteins and Variants and Uses Therefore Relating to Utrophin Induction for Muscular Dystrophy Therapy
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,526,759Activin-actriia antagonists and uses for treating or preventing breast cancer
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,624,301Polynucleotides Encoding an Actriib Antibody
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 9,493,556Actriia Binding Agents and Uses Thereof
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited